Evommune Secures $125.3M in Private Placement to Fund Clinical Programs
EVMN has more than doubled off its 52-week low of $13.885 on light trading volume (0.3× avg).
Summary
Evommune, Inc. announced a private placement of 4.5 million common shares at $27.88 per share, raising approximately $125.3 million to support its ongoing clinical development.
Key Events · Financing and Capital Events · EVMN
-
Significant Private Placement
Evommune completed a private placement on February 17, 2026, selling 4,494,279 common shares at $27.88 per share, raising approximately $125.3 million.
-
Funding for Clinical Development
The capital infusion is critical for advancing the company's clinical programs, including the planned Phase 2b trial for EVO756, following recent positive Phase 2a results.
-
Resale Registration Effective
A registration statement on Form S-1 for the resale of these privately placed shares was declared effective by the SEC on April 17, 2026.
-
Annual Shareholder Meeting Scheduled
The company will hold its virtual annual meeting on June 2, 2026, to elect two Class I directors and ratify the appointment of BDO USA, P.C. as its independent auditor.
Analysis · EVMN · Life Sciences
This definitive proxy statement reveals a significant capital raise through a private placement of common stock, which closed on February 17, 2026. The company sold 4,494,279 shares at a purchase price of $27.88 per share, generating gross proceeds of approximately $125.3 million. This substantial financing, representing about 12.4% of the company's market capitalization, was priced very close to the current market price, indicating strong investor confidence. The capital infusion is crucial for Evommune, a life sciences company, to advance its clinical programs, following recent positive Phase 2a results and plans for a Phase 2b trial. The filing also notes that a registration statement (Form S-1) for the resale of these shares was declared effective on April 17, 2026, providing liquidity for the investors.
How filings like this one have moved
In the 30 days to Sep 13, 2026, 35.3% of the 1324 measured filings Wiseek scored 8 moved their stock by 5% or more by the next session's close. The median move was -0.36%. These are measured outcomes after filings of this importance, not a forecast for this one.
Measured one observation per ticker per day, after exclusions. Current figures: Filing Impact Tracker · open dataset
At the time of this filing, EVMN was trading at $28.07 on NYSE in the Life Sciences sector, with a market capitalization of approximately $1B. The 52-week trading range was $13.89 to $33.20. This filing was assessed with positive market sentiment and an importance score of 8 out of 10.